| $385M | ||
| $337M | ||
| $100M | ||
| $87M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.
Over the last 12 months, insiders at Coya Therapeutics, Inc. have bought $0 and sold $0 worth of Coya Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Coya Therapeutics, Inc. have bought $55,007 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,800 shares for transaction amount of $12,934 was made by SNYDER DAVID S (Chief Financial Officer) on 2024‑11‑14.
| 2024-11-14 | SNYDER DAVID S | Chief Financial Officer | 1,800 0.0126% | $7.19 | $12,934 | -10.87% | ||
| 2024-11-13 | Swaminathan Arun | Chief Executive Officer | 5,000 0.0335% | $7.36 | $36,797 | -16.16% | ||
| 2024-11-11 | Swaminathan Arun | Chief Executive Officer | 5,000 0.0336% | $7.34 | $36,689 | -17.05% | ||
| 2024-11-11 | Grossman Fred | Chief Medical Officer | 2,710 0.0183% | $7.37 | $19,973 | -17.05% | ||
| 2023-08-22 | Lee Ann | director | 1,000 0.0104% | $3.62 | $3,620 | +94.16% | ||
| 2023-01-03 | Villalobos Anabella | director | 10,000 – | $0 | $0 | -2.15% | ||
| 2023-01-03 | Lee Ann | director | 10,000 – | $0 | $0 | -2.15% | ||
| 2023-01-03 | Hepner Adrian | Chief Medical Officer | 10,000 – | $0 | $0 | -2.15% | ||
| 2023-01-03 | GOLDSTEIN DOV A MD | director | 10,000 – | $0 | $0 | -2.15% | ||
| 2023-01-03 | Berman Howard | Chief Executive Officer | 10,000 – | $0 | $0 | -2.15% | ||
| 2023-01-03 | SNYDER DAVID S | Chief Financial Officer | 7,000 – | $0 | $0 | -2.15% | ||
| 2023-01-03 | Garren Hideki | director | 2,000 – | $0 | $0 | -2.15% |
| Lee Ann | director | 17479 0.1052% | $104,874.00 | 2 | 0 | +94.16% |
| GOLDSTEIN DOV A MD | director | 10000 0.0602% | $60,000.00 | 1 | 0 | |
| Hepner Adrian | Chief Medical Officer | 10000 0.0602% | $60,000.00 | 1 | 0 | |
| Villalobos Anabella | director | 10000 0.0602% | $60,000.00 | 1 | 0 | |
| Berman Howard | Chief Executive Officer | 10000 0.0602% | $60,000.00 | 1 | 0 | |
| Swaminathan Arun | Chief Executive Officer | 10000 0.0602% | $60,000.00 | 2 | 0 | |
| SNYDER DAVID S | Chief Financial Officer | 8800 0.053% | $52,800.00 | 2 | 0 | <0.0001% |
| Grossman Fred | Chief Medical Officer | 2710 0.0163% | $16,260.00 | 1 | 0 | |
| Garren Hideki | director | 2000 0.012% | $12,000.00 | 1 | 0 |
$155,580,641 | 77 | -24.21% | $114.6M | |
$4,898,715 | 46 | 40.75% | $108.25M | |
$7,147,964 | 34 | 24.78% | $113.33M | |
$160,539,875 | 21 | -6.57% | $95.84M | |
$3,331,968 | 17 | -23.79% | $92.06M | |
$7,733,516 | 17 | 73.42% | $102.37M | |
$245,302 | 15 | -4.08% | $94.64M | |
$18,563,605 | 15 | 48.91% | $91.5M | |
$277,862 | 15 | 59.79% | $96.74M | |
$15,799,576 | 12 | -39.52% | $95.32M | |
$145,194 | 11 | -27.37% | $98.11M | |
$135,589,307 | 10 | 32.46% | $101.15M | |
$2,762,881 | 8 | -10.76% | $113.47M | |
$5,524,590 | 7 | 7.40% | $115.21M | |
$99,355,998 | 7 | -65.74% | $119.94M | |
$68,692,148 | 6 | -39.10% | $107.12M | |
$657,791 | 4 | -52.05% | $91.68M | |
$105,079 | 4 | -41.57% | $93.67M | |
Coya Therapeutics, Inc. (COYA) | $16,554 | 2 | 41.65% | $99.69M |
| Increased Positions | 20 | +62.5% | 353,152 | +7.88% |
| Decreased Positions | 11 | -34.38% | 80,865 | -1.8% |
| New Positions | 9 | New | 80,095 | New |
| Sold Out Positions | 4 | Sold Out | 50,601 | Sold Out |
| Total Postitions | 41 | +28.13% | 5M | +6.07% |
| Dme Capital Management, Lp | $10,718.00 | 7.84% | 1.65M | 0 | 0% | 2025-09-30 |
| Aigh Capital Management Llc | $7,198.00 | 5.27% | 1.11M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $5,445.00 | 3.98% | 836,393 | -4,078 | -0.48% | 2025-09-30 |
| Cm Management, Llc | $1,953.00 | 1.43% | 300,000 | +100,000 | +50% | 2025-09-30 |
| Geode Capital Management, Llc | $1,021.00 | 0.75% | 156,845 | -242 | -0.15% | 2025-09-30 |
| Dauntless Investment Group, Llc | $996.00 | 0.73% | 153,021 | +101,932 | +199.52% | 2025-09-30 |
| Blackrock, Inc. | $455.00 | 0.33% | 69,958 | +1,702 | +2.49% | 2025-09-30 |
| Citadel Advisors Llc | $425.00 | 0.31% | 65,240 | +22,120 | +51.3% | 2025-09-30 |
| State Street Corp | $313.00 | 0.23% | 48,100 | 0 | 0% | 2025-09-30 |
| Marshall Wace, Llp | $272.00 | 0.2% | 41,825 | +41,825 | New | 2025-09-30 |